FIELD: medicine.
SUBSTANCE: there are offered compositions and methods for reducing orbital fat accumulation in a patient while treating a thyroid-associated ophthalmopathy, proptosis and related conditions (e.g. endocrinous ophthalmopathy). The compositions contain a beta-adrenergic agonist in the form of a crystalline microparticle suspension (e.g., prolonged release) for systemic injections or local introduction, and/or methylprednisolone acetate, fluticasone propionate in the form of the crystalline microparticle suspension as well. The methods involve the introduction of a compound for reducing beta-adrenergic receptor desensitisation (e.g. a corticosteroid) prior to the introduction or combined with the introduction of the beta-adrenergic agonist.
EFFECT: reduced weight of fat bodies and decreased volume of orbital fat after applying the declared compositions and methods.
39 cl, 7 dwg, 7 tbl, 6 ex
